https://www.nasdaq.com/press-release/abeona-therapeutics-issues-letter-to-shareholders-2021-12-22
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-pricing-of-public-offering-of-common-stock-and-warrants
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-public-offering-of-common-stock-and-warrants-2021-12-16
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-support-of-eb-research-partnerships-venture-into-cures
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-presentation-on-pivotal-transpher-a-study-of-abo-102-in
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-participation-at-the-jefferies-london-healthcare
https://www.nasdaq.com/press-release/abeona-therapeutics-reports-third-quarter-financial-results-2021-11-15
https://www.nasdaq.com/press-release/abeona-therapeutics-to-present-at-jefferies-gene-therapy-editing-summit-2021-10-21
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-clinical-data-presentations-at-upcoming-scientific
https://www.nasdaq.com/press-release/abeona-therapeutics-appoints-gene-therapy-quality-leader-jon-voss-as-vice-president
https://www.nasdaq.com/press-release/abeona-announces-new-chairman-executive-leadership-promotions-and-key-talent
https://www.nasdaq.com/press-release/abeona-therapeutics-to-present-at-upcoming-investor-conferences-2021-09-07
https://www.nasdaq.com/press-release/abeona-therapeutics-appoints-edward-carr-as-chief-financial-officer-2021-08-10
https://www.nasdaq.com/press-release/abeona-therapeutics-reports-second-quarter-financial-results-2021-07-28
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-successful-type-b-meeting-with-u.s.-fda-for-abo-102-aav
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-new-mri-data-showing-increased-brain-volume-in-young
https://www.nasdaq.com/press-release/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-updated-eb-101-phase-1-2a-clinical-results-in-recessive
https://www.nasdaq.com/press-release/abeona-therapeutics-to-present-at-jefferies-virtual-healthcare-conference-2021-06-02
https://www.nasdaq.com/press-release/abeona-therapeutics-issues-letter-to-stockholders-2021-05-26
https://www.nasdaq.com/press-release/abeona-therapeutics-appoints-head-of-research-clinical-development-2021-05-25
https://www.nasdaq.com/press-release/abeona-therapeutics-reports-first-quarter-financial-results-2021-05-18
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-presentation-on-new-preclinical-data-supporting-the
https://www.nasdaq.com/press-release/abeona-therapeutics-appoints-two-industry-leaders-as-new-independent-members-to-its
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-appointment-of-two-new-independent-members-to-its-board
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-2020-financial-results-and-recent-operational-progress
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-appointment-of-michael-amoroso-as-chief-executive
https://www.nasdaq.com/press-release/abeona-therapeutics-to-present-at-the-10th-annual-svb-leerink-global-healthcare
https://www.nasdaq.com/press-release/new-positive-phase-1-2-interim-data-presented-at-worldsymposiumtm-shows
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-clinical-investigator-webinar-to-review-abo-102-and-abo
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-successful-type-b-meeting-with-fda-for-pivotal-phase-3
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-acceptance-of-late-breaker-abstracts-highlighting-new
https://www.nasdaq.com/press-release/abeona-therapeutics-reports-third-quarter-financial-results-2020-11-09
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-the-appointment-of-michael-amoroso-as-chief-operating
https://www.nasdaq.com/press-release/abeona-therapeutics-board-of-directors-forms-special-committee-to-oversee-operations
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-leadership-and-board-transitions-2020-09-28
https://www.nasdaq.com/press-release/abeona-therapeutics-to-participate-in-upcoming-investor-conferences-2020-09-08
https://www.nasdaq.com/press-release/abeona-therapeutics-and-taysha-gene-therapies-enter-into-licensing-and-inventory
https://www.nasdaq.com/press-release/abeona-therapeutics-reports-second-quarter-financial-results-and-business-updates-0
https://www.nasdaq.com/press-release/abeona-therapeutics-reports-second-quarter-financial-results-and-business-updates
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-two-presentations-related-to-its-rdeb-clinical-program
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-appointment-of-michael-amoroso-as-chief-commercial
https://www.nasdaq.com/press-release/abeona-therapeutics-reinitiates-enrollment-in-eb-101-pivotal-phase-3-viitaltm-study
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-upcoming-data-presentations-at-the-society-for
https://www.nasdaq.com/press-release/abeona-therapeutics-further-strengthens-board-with-appointment-of-two-new-independent
https://www.nasdaq.com/press-release/abeona-therapeutics-to-present-at-the-jefferies-2020-virtual-healthcare-conference
https://www.nasdaq.com/press-release/abeona-therapeutics-reports-first-quarter-financial-results-and-business-updates-2020
https://www.nasdaq.com/press-release/abeona-therapeutics-reports-first-quarter-financial-results-and-business-updates-0
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2020
https://www.nasdaq.com/press-release/abeona-therapeutics-appoints-brian-pereira-and-shawn-tomasello-to-the-board-of
https://www.nasdaq.com/press-release/abeona-therapeutics-stakeholder-letter-in-response-to-the-covid-19-pandemic-2020-03
https://www.nasdaq.com/press-release/abeona-therapeutics-stakeholder-letter-in-response-to-the-covid-19-pandemic-2020-03-0
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-first-patient-treated-in-pivotal-phase-iii-clinical
https://www.nasdaq.com/press-release/abeona-therapeutics-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/abeona-therapeutics-to-present-at-the-9th-annual-svb-leerink-global-healthcare
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-positive-interim-data-from-mps-iii-gene-therapy
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-participation-in-inaugural-world-congress-on
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-issuance-of-u.s.-patent-for-aimtm-capsids-2020-01-15
https://www.nasdaq.com/press-release/abeona-therapeutics-initiates-pivotal-phase-3-clinical-trial-evaluating-eb-101-gene
https://www.nasdaq.com/press-release/abeona-announces-closing-of-%24103.5-million-underwritten-public-offering-and-full
https://www.nasdaq.com/press-release/abeona-announces-pricing-of-public-offering-of-common-stock-and-pre-funded-warrants
https://www.nasdaq.com/press-release/abeona-therapeutics-receives-european-medicines-agency-prime-designation-for-abo-102
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-public-offering-of-common-stock-and-pre-funded-warrants
https://www.nasdaq.com/press-release/abeona-therapeutics-cleared-to-initiate-pivotal-phase-3-clinical-trial-evaluating-eb
https://www.nasdaq.com/press-release/shareholder-alert%3a-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-32
https://www.nasdaq.com/press-release/abeona-therapeutics-reports-third-quarter-2019-financial-results-and-business-updates
https://www.nasdaq.com/press-release/rosen-a-leading-global-law-firm-announces-filing-of-securities-class-action-lawsuit
https://www.nasdaq.com/press-release/investor-alert-abeona-therapeutics-inc.-abeo-bronstein-gewirtz-grossman-llc-notifies
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-presentations-at-the-27th-european-society-of-gene-and
https://www.nasdaq.com/press-release/abeona-therapeutics-announces-publication-of-positive-long-term-data-from-phase-1-2a
https://www.nasdaq.com/press-release/lifshitz-miller-llp-announces-investigation-of-abeona-therapeutics-inc.-aptinyx-inc.
https://www.nasdaq.com/press-release/abeona-therapeutics-provides-regulatory-update-ahead-of-pivotal-phase-3-clinical
